Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...

Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive ...

Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for ...